Your browser doesn't support javascript.
loading
SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling.
Zhao, Bao; Gong, Weipeng; Ma, Anjun; Chen, Jianwen; Velegraki, Maria; Dong, Hong; Liu, Zihao; Wang, Lingling; Okimoto, Tamio; Jones, Devin M; Lei, Yu L; Long, Meixiao; Oestreich, Kenneth J; Ma, Qin; Xin, Gang; Carbone, David P; He, Kai; Li, Zihai; Wen, Haitao.
Afiliação
  • Zhao B; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Gong W; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Ma A; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Chen J; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
  • Velegraki M; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Dong H; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Liu Z; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Wang L; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Okimoto T; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Jones DM; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
  • Lei YL; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Long M; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA.
  • Oestreich KJ; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Ma Q; Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.
  • Xin G; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Carbone DP; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
  • He K; Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Li Z; Pelotonia Institute for Immuno-Oncology, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Wen H; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Nat Immunol ; 23(11): 1588-1599, 2022 11.
Article em En | MEDLINE | ID: mdl-36266363
ABSTRACT
Dysfunctional CD8+ T cells, which have defective production of antitumor effectors, represent a major mediator of immunosuppression in the tumor microenvironment. Here, we show that SUSD2 is a negative regulator of CD8+ T cell antitumor function. Susd2-/- effector CD8+ T cells showed enhanced production of antitumor molecules, which consequently blunted tumor growth in multiple syngeneic mouse tumor models. Through a quantitative mass spectrometry assay, we found that SUSD2 interacted with interleukin (IL)-2 receptor α through sushi domain-dependent protein interactions and that this interaction suppressed the binding of IL-2, an essential cytokine for the effector functions of CD8+ T cells, to IL-2 receptor α. SUSD2 was not expressed on regulatory CD4+ T cells and did not affect the inhibitory function of these cells. Adoptive transfer of Susd2-/- chimeric antigen receptor T cells induced a robust antitumor response in mice, highlighting the potential of SUSD2 as an immunotherapy target for cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article